C12N 2760/18871
Demonstrated in vivo effect
C12N2760/18871 (Demonstrated in vivo effect) appears on 8 US grants and 14 published applications in this corpus.
Search patents in C12N- Granted patents
- 8
- Published applications
- 14
- Assignees
- 10
- Inventors
- 40
- Latest grant
- 9 Nov 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 2 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 2 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 1 |
| 2017 | 0 | 2 |
| 2018 | 0 | 1 |
| 2019 | 2 | 2 |
| 2020 | 1 | 0 |
| 2021 | 1 | 0 |
By publication year.
Recent patents
- Anticancer agent comprising HVJ-E and immune checkpoint protein inhibitor9 Nov 2021US 11,166,995 B2Genomidea Inc.
- Optimized HIV envelope gene and expression thereof6 Oct 2020US 10,792,357 B2International AIDS Vaccine Initiative
- Anti-cancer agent comprising HVJ-E and CXCL215 Oct 2019US 10,441,613 B2Genomidea Inc.
- Optimized HIV envelope gene and expression thereof5 Mar 2019US 10,220,087 B2International AIDS Vaccine Initiative
- Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic Sendai virus27 Dec 2016US 9,526,779 B2
- Anticancer agent comprising hvj-e and immune checkpoint protein inhibitor12 Sep 2019US 2019/0275091 A1Genomidea Inc.
- Optimized hiv envelope gene and expression thereof4 Jul 2019US 2019/0201522 A1International AIDS Vaccine Initiative
- Anti-cancer agent comprising hvj-e and cxcl230 Aug 2018US 2018/0243355 A1Genomldea Inc.
- Genetically stable replication competent sendai virus vector(s) containing and expressing optimized hiv genes14 Sep 2017US 2017/0258890 A1
- Optimized hiv envelope gene and expression thereof14 Sep 2017US 2017/0258891 A1International AIDS Vaccine Initiative
Most cited
By later US patents